SPONSOR

Gilead Sciences

Total Trials

Recruiting

Phases

Phase 1, Phase 2, Phase 3, Phase 2, Phase 3, Phase 1, Phase 4

Conditions studied: HIV Infections Chronic Hepatitis Delta HIV Pre-exposure Prophylaxis HIV-1-infection Advanced Solid Tumors Triple Negative Breast Cancer Advanced Solid Tumor

Gilead Sciences is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including HIV Infections, Chronic Hepatitis Delta, HIV Pre-exposure Prophylaxis, HIV-1-infection.

The trial portfolio spans Phase 1, Phase 2, Phase 3, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Gilead Sciences

How many clinical trials has Gilead Sciences sponsored?

ClinicalMetric currently tracks 9 clinical trials sponsored by Gilead Sciences, of which 9 are actively recruiting participants. These trials cover conditions including HIV Infections, Chronic Hepatitis Delta, HIV Pre-exposure Prophylaxis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Gilead Sciences research focus on?

Gilead Sciences clinical trials span HIV Infections, Chronic Hepatitis Delta, HIV Pre-exposure Prophylaxis, HIV-1-infection, Advanced Solid Tumors, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 3, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Gilead Sciences clinical trial?

To participate in a Gilead Sciences trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Gilead Sciences trials with current recruitment status updated daily.

Clinical Trials by Gilead Sciences

NCT07473778

Recruiting

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

HIV Infections

NCT07096193 Phase 1, Phase 2

Recruiting

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Chronic Hepatitis Delta

NCT07047716 Phase 3

Recruiting

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

HIV Pre-exposure Prophylaxis

NCT06532656 Phase 2, Phase 3

Recruiting

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

HIV-1-infection

NCT06167317 Phase 1

Recruiting

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Advanced Solid Tumors

NCT06532565 Phase 1

Recruiting

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Advanced Solid Tumors

NCT06337032 Phase 4

Recruiting

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection

NCT06926920 Phase 1, Phase 2

Recruiting

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Triple Negative Breast Cancer

NCT07128303 Phase 1

Recruiting

Study of GS-5319 in Adults With Solid Tumors

Advanced Solid Tumor

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology